- Company
- Samsung Biologics, ranked No.1 in the market cap
- by An, Kyung-Jin May 11, 2020 06:19am
- Samsung Biologics is taking third place in the market capitalization of KOSPI with the reflex profit of COVID-19. Difference in market capitalization with Celltrion is about &8361;10 trillion, and it has been holding a position as a bio leading stock for 7 months. According to the Korea Exchange on the 8th, Samsung Biologics closed th
- Company
- COVID-19 affected off-patent drug market share plunge?
- by Chon, Seung-Hyun May 11, 2020 06:18am
- Although off-patent originals have been consistently expanded their market shares in recent years unaffected by the army of generics entering the market, the original’s market share shrunk in last first quarter. The Korean pharmaceutical industry experts analyze the originals struggled to grow in the market against intense marketing of generics
- Policy
- Will generic for Nexavar be released?
- by Lee, Tak-Sun May 11, 2020 06:18am
- The attention is focused whether the generic drug of Nexavar (Sorafenib, Bayer) which has an absolute position as the first drug for liver cancer will be available in the market soon or not. Access to the patient is expected to improve further if the generic for Nexavar which has established an almost exclusive position in the liver cance
- Policy
- Treatment standards are changed in the early stage of MDR-TB
- by Kim, Jung-Ju May 11, 2020 06:17am
- In order to combat multidrug-resistant tuberculosis (MDR-TB), health authorities have changed treatment standards so that new drugs such as Bedaquiline can be used as core drugs even in the early stages of disease. This is to increase the success rate of treatment. The KCDC (Director Eun-Kyeong Jung) has published Korean guidelines for tuberc
- Product
- Fexuprazan taking over K-CAB market? Study unveiled
- by choi, sun May 11, 2020 06:15am
- As Daewoong Pharmaceutical unveiled Phase III clinical data of its next-generation gastroesophageal reflux disease agent in development, fexuprazan, the Korean pharmaceutical industry is keeping a close eye on the prospective competition between the existing proton pump inhibitors (PPI) tegoprazan (Brand name: K-CAB) and the novel agent. Reve
- Company
- Zolgensma & Kymriah will be entered the Korean market
- by Eo, Yun-Ho May 8, 2020 06:34am
- Two very expensive new drugs by Novartis enter the Korean market. According to a related industry, Novartis Korea submitted an application for the approval of a treatment for Spinal Muscular Atrophy (SMA), Zolgensma (Onasemnogene abeparvovec) & CAR-T (Chimeric Antigen Receptor T cells) cell gene therapy, Kymriah (Tisagenlecleucel) earlier
- Policy
- Felodipine indication to get limited to stable angina
- by Lee, Tak-Sun May 8, 2020 06:34am
- Felodipine, used on patients with hypertension and angina, is facing an indication adjustment to only treat stable angina when used for angina. Korea Ministry of Food and Drug Safety (MFDS) is planning to finalize the order to change the medicine’s indication on May 22. A calcium channel blocker (CCB), felodipine has a brand-name drug l
- Company
- Jeil got a domestic exclusive promotion for Amitiza
- by Lee, Seok-Jun May 8, 2020 06:34am
- Jeil distributes FDA-approved constipation drugs in Korea. Jeil announced on the 6th that it has signed an exclusive promotional contract (distribution, marketing, and sales rights) in Korea with Amitiza soft capsule (Lubiprostone), a chronic constipation treatment for Takeda. Amitiza received FDA approval in 2006. In Korea, the approva
- InterView
- I tried to make the KOEDC 'Social butterfly '
- by Lee, Jeong-Hwan May 8, 2020 06:34am
- “The KOEDC (Korea Orphan & Essential Drug Center) is the place where the government and the public need attention more than any other institution. I wanted to increase the utilization of the public by spreading the awareness to the society that it is a place to supply medicines that are essential for the treatment of incurable patients and t
- Opinion
- Time to stop the delay in drug patent conflict
- by May 8, 2020 06:33am
- The world bombarded with COVID-19 related news has been disheartening. Even the new coined term ‘Corona Blue’ was trending. But on the lighter side, I came across some good news for myself, who mainly lectures and researches on patent law depicted in news articles. It was from a global pharmaceutical company, AbbVie announcing it would giv
